http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0989114-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5dfc0b033ac4c841466d97a5f28ea32b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C233-01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D407-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-56 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C233-01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D407-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-66 |
| filingDate | 1997-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2002-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_715bf9b52e236d5d66cec00357565b85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e3c2810aebc5cc2c2a3535f0f186fb6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e12efd08d80207e3284d2669173f201 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e32e01285b634a8ebc1787cf8e89ff28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cdef9d58b9ef056e863573601c9863b9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82ed778400e5d64cd17d4d1adc900b21 |
| publicationDate | 2002-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0989114-B1 |
| titleOfInvention | N,n-disubstituted amic acid derivatives |
| abstract | PCT No. PCT/JP97/00305 Sec. 371 Date Aug. 4, 1998 Sec. 102(e) Date Aug. 4, 1998 PCT Filed Feb. 7, 1997 PCT Pub. No. WO97/29074 PCT Pub. Date Aug. 14, 1997A compound represented by general formula (I) or a pharmaceutically acceptable salt or ester thereof: [wherein each of Ar1, Ar2, Ar3 and Ar4 is an aryl group or an aromatic heterocyclic group; A1 is a C2-6 chain hydrocarbon group or a group represented by -A1a-W1-A1b- (wherein W1 is an oxygen atom, a sulfur atom, an ethynylene group, a cyclopropylene group or a group represented by -NRW-; A2 is a C2-8 chain hydrocarbon group; each of X and Y is an oxygen atom, a sulfur atom, a carbonyl group or a group represented by -CHRa- or by -NRb-, or X and Y together represent a vinylene group or an ethynylene group; each of R1, R2, R3, R7 and R8 is a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group, a lower alkenyl group or a lower alkoxy group; each of R4 and R5 is a hydrogen atom, a halogen atom, a hydroxyl group, an amino group, a nitro group, a cyano group, a carboxyl group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkyl group, a lower hydroxyalkyl group, a lower fluoroalkyl group or a lower alkoxy group; and R6 is a lower alkyl group, provided that when one of X and Y is an oxygen atom, a sulfur atom or a group represented by -NRb-, the other is a carbonyl group or a group represented by -CHRa- and an antitumor agent comprising it as an active ingredient. |
| priorityDate | 1996-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 775.